Coherus BioSciences

Coherus BioSciences is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative immunotherapies to treat cancer. They are dedicated to extending patient survival across various tumor types, leveraging both their established infrastructure in biosimilars and a robust pipeline of next-generation immuno-oncology treatments. Coherus currently markets LOQTORZI (toripalimab-tpzi), the first FDA-approved therapy for the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC), alongside other biosimilar therapies.

Their immuno-oncology pipeline consists of multiple antibody immunotherapy candidates that aim to enhance both innate and adaptive immune responses to cancer. Their key programs include Casdozokitug, a novel anti-IL-27 antibody currently in clinical trials for lung and liver cancer; CHS-114, a highly selective anti-CCR8 antibody in Phase 1/2 studies for advanced solid tumors; and CHS-1000, a preclinical program targeting the ILT4 pathway which is expected to enter clinical trials in 2024. These programs are all designed to inhibit immune suppressive mechanisms in the tumor microenvironment, with the goal of delivering powerful anti-tumor activity and ultimately transforming outcomes for patients.

Coherus BioSciences values employee work-life balance and offers flexibility in their work arrangements. They encourage employees to find the right balance and offer various activities, perks, and holidays to promote a healthy outlook and encourage employees to spend time outside of work with friends and family. They also foster a collaborative work environment and encourage agile thinking, allowing employees to have a voice and contribute their ideas.

Coherus BioSciences offers a comprehensive total rewards program that includes competitive base pay, performance-based cash and equity incentives, and a robust health and wellness package. Their health insurance plan covers 90% of premiums for employees, their eligible spouses, dependents, and domestic partners, and they also provide health savings and flexible spending accounts. Other benefits include group life, disability, and accident insurance, a 401(k) plan with company match, an Employee Stock Purchase Plan, paid time off, and various health and wellness programs such as a health club reimbursement and employee assistance program.

Coherus BioSciences is a fully integrated biopharmaceutical company focused on developing and commercializing innovative immunotherapies to treat cancer and deliver better treatment access and outcomes for patients with life-altering illnesses. They are committed to advancing a diversified portfolio of next-generation immuno-oncology therapies to transform cancer treatment and extend survival for patients with hard-to-treat tumors. Their mission is to deliver medicines that make a difference for people with life-altering diseases.

Coherus BioSciences promotes a performance-driven, team-focused, and thoughtful culture that prioritizes patient well-being. They value a high level of intellect, experience, and competency, expecting employees to demonstrate initiative and take responsibility for their work. Decision-making is collaborative and iterative, emphasizing open communication and diverse perspectives. While maintaining a strong work ethic, the company encourages a healthy work-life balance and provides a supportive environment for professional growth.

Coherus BioSciences is committed to fostering a diverse, equitable, and inclusive workplace. They strive to create an environment where all employees feel valued, respected, and have the opportunity to contribute their unique skills and perspectives. Their commitment to DEI is evident in their hiring practices, employee resource groups, and a culture that promotes open communication and celebrates differences. They believe that a diverse workforce leads to better decision-making, innovation, and overall success.